PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer

Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being activel...

Full description

Bibliographic Details

Published in:	Precision and Future Medicine
Main Author:	Jong-Mu Sun
Format:	Article
Language:	English
Published:	Sungkyunkwan University School of Medi 2017-03-01
Subjects:	Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor
Online Access:	http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf